EGEN-001: Phase I started

Egen said the Gynecologic Oncology Group (GOG) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 18-36 mg/m 2 intraperitoneal EGEN-001 weekly plus IV pegylated liposomal doxorubicin...